Remote monitoring strategies are increasingly being evaluated in the management of heart failure (HF). Updated findings from the PROACTIVE-HF trial, published in the Journal of Cardiac Failure, assessed clinical outcomes over a two-year period in patients with HF managed using a pulmonary artery (PA) pressure sensor system.

PROACTIVE-HF was a prospective, multicenter, open-label, single-arm study evaluating remote HF management using a PA pressure sensor integrated with monitoring of vital signs and patient-reported symptoms. Eligible participants had HF with New York Heart Association (NYHA) class III symptoms, irrespective of ejection fraction (EF). Management incorporated seated mean pulmonary artery pressure (mPAP) measurements together with digital platform monitoring.

During the first 24 months of follow-up, the incidence of heart failure events or death (HFE/D) was 0.89 events per patient (95% confidence interval [CI]: 0.81–0.99), with events primarily driven by heart failure hospitalizations (HFH). When stratified by EF category, patients with heart failure with reduced ejection fraction (HFrEF) had higher HFE/D rates than those with heart failure with preserved ejection fraction (HFpEF) (1.0 vs 0.8 events per patient; p = 0.048).

Across the study population, management using a PA pressure sensor system was associated with low event rates and improved health status at two years regardless of EF. Remote monitoring incorporated vital signs, seated PA pressure measurements, and patient-reported symptoms through a digital platform.